-
Product Insights
New![]()
Higher Stockbridge Solar PV Park
Higher Stockbridge Solar PV Park is a solar PV project located in England, United Kingdom. The project is owned and developed by Voltalia UK Ltd. The project is currently under construction. Empower your strategies with our Higher Stockbridge Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections...
-
Analyst Opinions
New![]()
Premiumization and Indulgence – Consumer TrendSights Analysis, 2023
Trendsights Analysis on Premiumization & Indulgence explores how consumers seek premium products in all categories in the market. The trend is a part of the Sensory & Indulgence mega-trend, and focuses on how brands provide added value to their premium goods to make them more appealing and sophisticated. During times of busy lifestyles and poor work-life balance, consumers seek products that will help them relax, ease anxiety and provide the feeling of treating themselves. Thus, individuals look for goods which...
-
Sector Analysis
New![]()
Saudi Arabia Retail Banking Competitor Benchmarking – Financial Performance, Customer Relationships and Satisfaction
This report looks at market performance, retention risk, and market shares across key products within Saudi Arabia’s retail banking space. It also ranks the market’s leading banks across a range of criteria, from digital adoption and user experience to rewards and money management tools. Higher interest rates in 2022 resulted in increased net interest incomes for the majority of Saudi banks. Nonetheless, most banks’ net interest margins were squeezed as a result of rate hikes. In terms of market power,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CC-91633 in Myelodysplastic Syndrome
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CC-91633 in Myelodysplastic Syndrome Drug Details:CC-91633 (BMS-986397) is under development for the treatment of relapsed or refractory...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Eragidomide in Refractory Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Eragidomide in Refractory Acute Myeloid Leukemia Drug Details: Eragidomide (CC-90009) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CC-91633 in Relapsed Acute Myeloid Leukemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CC-91633 in Relapsed Acute Myeloid Leukemia Drug Details:CC-91633 (BMS-986397) is under development for the treatment of relapsed...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Eragidomide in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Eragidomide in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Drug Details: Eragidomide (CC-90009) is under...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Eragidomide in Myelodysplastic Syndrome
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Eragidomide in Myelodysplastic Syndrome Drug Details: Eragidomide (CC-90009) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CC-91633 in Refractory Acute Myeloid Leukemia
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CC-91633 in Refractory Acute Myeloid Leukemia Drug Details:CC-91633 (BMS-986397) is under development for the treatment of relapsed...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Eragidomide in Relapsed Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Eragidomide in Relapsed Acute Myeloid Leukemia Drug Details: Eragidomide (CC-90009) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Semaglutide Injection in Diabetes
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Semaglutide Injection in Diabetes Drug Details: Semaglutide injection is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Anzurstobart in Head And Neck Squamous Cell Carcinoma (HNSC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Anzurstobart in Head And Neck Squamous Cell Carcinoma (HNSC) Drug Details: CC-95251 is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Anzurstobart in Mantle Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Anzurstobart in Mantle Cell Lymphoma Drug Details: CC-95251 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Anzurstobart in Marginal Zone B-cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Anzurstobart in Marginal Zone B-cell Lymphoma Drug Details: CC-95251 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Anzurstobart in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Anzurstobart in Solid Tumor Drug Details: CC-95251 is under development for the treatment of colorectal...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Anzurstobart in Relapsed Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Anzurstobart in Relapsed Acute Myeloid Leukemia Drug Details: CC-95251 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Anzurstobart in Refractory Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Anzurstobart in Refractory Acute Myeloid Leukemia Drug Details: CC-95251 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Anzurstobart in Myelodysplastic Syndrome
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Anzurstobart in Myelodysplastic Syndrome Drug Details: CC-95251 is under development for the treatment of colorectal...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SL-172154 in Myelodysplastic Syndrome
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. SL-172154 in Myelodysplastic Syndrome Drug Details: SL-172154 is under development for the treatment of advanced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SL-172154 in Refractory Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. SL-172154 in Refractory Acute Myeloid Leukemia Drug Details: SL-172154 is under development for the treatment...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.